calcifediol


Also found in: Wikipedia.

calcifediol

 [kal″sĭ-fĕ-di´ol]
25-hydroxycholecalciferol (a form of vitamin D), used in the treatment of hypocalcemia, hypophosphatemia, rickets, and osteodystrophy associated with various medical conditions including chronic renal failure and hypoparathyroidism, administered orally.

cal·ci·di·ol

(kal-sĭ-dī'ol),
First step in the biologic conversion of vitamin D3 to the more active form, calcitriol; it is more potent than vitamin D3.

calcifediol

/cal·cif·e·di·ol/ (kal″sif-ĕ-di´ol) see 25-hydroxycholecalciferol.

calcifediol

[kal′sifē′dē·ol]
a major transport form of vitamin D.
indication It is prescribed in the treatment of metabolic bone disease associated with chronic renal failure.
contraindications Hypercalcemia, vitamin D toxicity, malabsorption syndrome, decreased renal function, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the most serious adverse effects are renal toxicity and those reactions associated with hypercalcemia, such as soft tissue calcification and GI and central nervous system disturbances.

calcifediol

nonproprietary name for 25-hydroxycholecalciferol, used as a calcium regulator in the treatment and management of metabolic bone disease or hypocalcemia associated with chronic renal failure.
References in periodicals archive ?
In 2016, a third study looked at functional status among 200 elderly men and women in a three-armed randomization: a low-dose control group receiving 24,000 IU of vitamin D; 60,000 IU vitamin D3; or 24,000 IU of vitamin plus 300 meg calcifediol.
3]) 400 to 2000 IU/d for 4 months to 5 years or 100,000 to 500,000 IU every 3 to 12 months for 1 to 5 years; calcifediol (25(OH) [D.
En un articulo relacionado y que ha sido publicado en el JAMA Internal Medicine sobre suplementacion de vitamina D y su asociacion con el riesgo de caidas (9), se encuentra que las dosis altas (vitamina D3 60 000 UI por mes o 24 000 UI mas 300 mg of calcifediol por mes) permitio alcanzar niveles de 25-hidroxivitamina D (25[OH]D) de 30 ng/mL en 80% de los participantes, dosis recomendada para reducir el riesgo de fracturas y otros beneficios.
Jetter e colaboradores (2014), igualmente, se detiveram a estudar a melhor forma de administracao da vitamina D, atraves da oferta, para mulheres em pos-menopausa (50 a 70 anos), de: 20[micron]g/dia de calcifediol (n = 5; por 15 semanas); 20[micron]g/dia de vitamina D3 (colecalciferol; n = 5; por 15 semanas); 140[micron]g/semana de calcifediol (n = 5; por 15 semanas); 140[micron]g/semana vitamina D3 (n = 5; por 15 semanas); dose unica de 140[micron]g de calcifediol (n = 5); dose unica de 140[micron]g de vitamina D3 (n = 5); dose unica com 140[micron]g de calcifediol 140[micron]g de vitamina D3 (n = 5).
Researchers assigned 30 women with fibromyalgia and low levels of calcifediol, a marker of vitamin D, to either a treatment or a control group.
The goal for the treatment group was to achieve serum calcifediol levels between 32 and 48 ng/mL for 20 weeks.
Researchers speculate that vitamin D supplements might reduce the degree of chronic pain in people with low levels of calcifediol (also known as calcidiol, a marker of vitamin D levels in the body).
Researchers hypothesized that vitamin D supplementation would reduce the degree of chronic pain experienced by FMS patients with low levels of calcifediol and also might improve other symptoms.
Calcitriol is structurally similar to calcifediol, but calcitriol has more than twice the vitamin D activity of calcifediol.
There are different types of vitamin D, and these could be either DHT, calcitriol, or calcifediol.
The study Calcifediol (CAS 19356-17-3) Market Research Report 2010 presents an overview of the Calcifediol market globally and regionally by contemplating and analyzing its parameters.
OPKO's poster presentation entitled "Extended-release Calcifediol is Effective in African-American and Non-African-American Patients with Stage 3-4 CKD, Secondary Hyperparathyroidism and Vitamin D Insufficiency," will be presented by senior author Stuart M.